📣 Notice: Short Maintenance Tonight (May 19th)
Due to increasing user numbers, we’re upgrading our servers this evening. StocksGuide will be unavailable for about 5–10 minutes between 4:00 PM and 5:00 PM (EDT / New York time). Afterwards, you’ll continue to benefit from fast and stable site performance. Thank you for your understanding! Your StocksGuide Team

$0.69
0.74%
Nasdaq, May 16, 10:00 pm CET
ISIN
US6402681083
Symbol
NKTR
Reports
Quarter | Annual
Index
NASDAQ Composite
Sector
Health
Industry
Biotechnology

Nektar Therapeutics Target price 2025 - Analyst rating & recommendation

Nektar Therapeutics Classifications & Recommendation:

Buy
75%
Hold
13%
Sell
13%

Nektar Therapeutics Price Target

Target Price $4.92
Price $0.69
Potential
617.76%
register free of charge
Number of Estimates 6
6 Analysts have issued a price target Nektar Therapeutics 2026 . The average Nektar Therapeutics target price is $4.92. This is
617.76%
register free of charge
higher than the current stock price. The highest price target is
$7.00 921.90%
register free of charge
, the lowest is
$2.00 191.97%
register free of charge
.
A rating was issued by 8 analysts: 6 Analysts recommend Nektar Therapeutics to buy, 1 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Nektar Therapeutics stock has an average upside potential 2026 of
617.76%
register free of charge
. Most analysts recommend the Nektar Therapeutics stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 98.43 40.02
9.22% 59.34%
EBITDA Margin -130.78% -322.34%
9.06% 146.47%
Net Margin -109.66% -374.34%
63.38% 241.37%

8 Analysts have issued a sales forecast Nektar Therapeutics 2025 . The average Nektar Therapeutics sales estimate is

$40.0m
Unlock
. This is
54.13% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$48.1m 44.90%
Unlock
, the lowest is
$10.5m 87.97%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $98.4m 9.22%
2025
$40.0m 59.34%
Unlock
2026
$40.9m 2.26%
Unlock
2027
$35.4m 13.58%
Unlock
2028
$43.2m 22.09%
Unlock
2029
$110m 155.61%
Unlock

1 Analyst has issued an EBITDA forecast Nektar Therapeutics 2025 . The average Nektar Therapeutics EBITDA estimate is

$-129m
Unlock
. This is
5.58% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-129m 5.58%
Unlock
, the lowest is
$-129m 5.58%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-129m 0.68%
2025
$-129m 0.21%
Unlock
2026
$-151m 17.05%
Unlock
2027
$-191m 26.56%
Unlock

EBITDA Margin

2024 -130.78% 9.06%
2025
-322.34% 146.47%
Unlock
2026
-368.97% 14.47%
Unlock
2027
-540.32% 46.44%
Unlock

8 Nektar Therapeutics Analysts have issued a net profit forecast 2025. The average Nektar Therapeutics net profit estimate is

$-150m
Unlock
. This is
25.78% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-114m 4.69%
Unlock
, the lowest is
$-184m 54.69%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-108m 60.00%
2025
$-150m 38.79%
Unlock
2026
$-149m 0.62%
Unlock
2027
$-170m 14.52%
Unlock
2028
$-248m 45.18%
Unlock
2029
$-254m 2.82%
Unlock

Net Margin

2024 -109.66% 63.38%
2025
-374.34% 241.37%
Unlock
2026
-363.79% 2.82%
Unlock
2027
-482.05% 32.51%
Unlock
2028
-573.19% 18.91%
Unlock
2029
-230.57% 59.77%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.58 -0.81
60.00% 39.66%
P/E negative
EV/Sales 2.39

8 Analysts have issued a Nektar Therapeutics forecast for earnings per share. The average Nektar Therapeutics EPS is

$-0.81
Unlock
. This is
26.56% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.61 4.69%
Unlock
, the lowest is
$-0.99 54.69%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.58 60.00%
2025
$-0.81 39.66%
Unlock
2026
$-0.80 1.23%
Unlock
2027
$-0.92 15.00%
Unlock
2028
$-1.33 44.57%
Unlock
2029
$-1.37 3.01%
Unlock

P/E ratio

Current -1.08 43.46%
2025
-0.85 21.30%
Unlock
2026
-0.86 1.18%
Unlock
2027
-0.75 12.79%
Unlock
2028
-0.52 30.67%
Unlock
2029
-0.50 3.85%
Unlock

Based on analysts' sales estimates for 2025, the Nektar Therapeutics stock is valued at an EV/Sales of

2.39
Unlock
and an P/S ratio of
3.19
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.09 63.05%
2025
2.39 118.95%
Unlock
2026
2.33 2.21%
Unlock
2027
2.70 15.71%
Unlock
2028
2.21 18.09%
Unlock
2029
0.87 60.88%
Unlock

P/S ratio

Current 1.46 59.23%
2025
3.19 118.02%
Unlock
2026
3.11 2.22%
Unlock
2027
3.60 15.71%
Unlock
2028
2.95 18.09%
Unlock
2029
1.16 60.88%
Unlock

Current Nektar Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Jefferies
Locked
➜
Locked
 Locked Apr 11 2025
Oppenheimer
Locked
➜
Locked
 Locked Mar 14 2025
HC Wainwright & Co.
Locked
➜
Locked
 Locked Mar 13 2025
HC Wainwright & Co.
Locked
➜
Locked
 Locked Feb 25 2025
HC Wainwright & Co.
Locked
➜
Locked
 Locked Jan 13 2025
B. Riley Securities
Locked
➜
Locked
 Locked Jan 08 2025
Piper Sandler
Locked
➜
Locked
 Locked Nov 04 2024
Analyst Rating Date
Locked
Jefferies:
Locked
➜
Locked
 Apr 11 2025
Locked
Oppenheimer:
Locked
➜
Locked
 Mar 14 2025
Locked
HC Wainwright & Co.:
Locked
➜
Locked
 Mar 13 2025
Locked
HC Wainwright & Co.:
Locked
➜
Locked
 Feb 25 2025
Locked
HC Wainwright & Co.:
Locked
➜
Locked
 Jan 13 2025
Locked
B. Riley Securities:
Locked
➜
Locked
 Jan 08 2025
Locked
Piper Sandler:
Locked
➜
Locked
 Nov 04 2024

Discover more stocks with a high price target

TUI 57.08%
Novo Nordisk 53.62%
BioNTech SE - ADR 44.95%
MongoDB 36.70%
NIO ADR 30.19%
Alibaba Group Holding Ltd 28.29%
Pfizer 23.80%
Tencent Holdings Ltd. 22.89%
Alphabet 19.17%
Infineon 18.68%
NVIDIA 18.58%
Adidas 18.29%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now
The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today